This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 138.0 kDa. The protein migrates as 150-200 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in PBS. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
SARS-CoV-2 S protein, His Tag, Super stable trimer on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
The purity of SARS-CoV-2 S protein, His Tag, Super stable trimer (Cat. No. SPN-C52H9) was more than 90% and the molecular weight of this protein is around 480-550 kDa verified by SEC-MALS.
The well-folded trimeric particles of SARS-CoV-2 S protein, His Tag, Super stable trimer (SPN-C52H9) was verified by negative stain electron micrography. The particles are similar in size and appearance to SARS-CoV-2 trimers reported in published literature.
Immobilized Human ACE2, Fc Tag (Cat. No. AC2-H5257) at 1 μg/mL (100 μL/well) can bind SARS-CoV-2 S protein, His Tag, Super stable trimer (Cat. No. SPN-C52H9) with a linear range of 1-39 ng/mL (QC tested).
Human ACE2, Fc Tag (Cat. No. AC2-H5257) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind SARS-CoV-2 S protein, His Tag, Super stable trimer (Cat. No. SPN-C52H9) with an affinity constant of 40.9 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Journal: Allegra Peletta, Eakachai Prompetchara, et al. Vaccines
Journal: Wang W, Li Q, Wu J, et al. Emerg Microbes Infect
Journal: Zupancic JM, Desai AA, Schardt JS, et al. Cell chemical biology
Journal: Charvet B, Mazelier M, Brunel J, et al. Research Square
Journal: Zhou D, Chan JF, Zhou B, et al. Cell Host Microbe
Journal: Ozono S, Zhang Y, Ode H, et al. Nature communications
Journal: Kazushige Yokoyama, Akane Ichiki Colloid and Interface Science Communications
Journal: Wei C, Wan L, Yan Q, et al. Nature metabolism
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Emerging VoCs, Lambda, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ELISA kits for neutralizing antibody titer assay, binding antibody titer assay, antibody isotype assay, antigen titer assay and inhibitor screening, etc., which can accelerate the research and development of anti-SARS-CoV-2 drugs and vaccines.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
This web search service is supported by Google Inc.